1 min read
Add as a preferred source on GoogleLiquidia Sets 2028 PH-ILD Goal, 2029 L606 NDA Submission Target
Liquidia Corporation plans to complete PH-ILD enrollment in 2028 and has a 2029 target for an L606 new drug application submission.
Liquidia Corporation is aiming to finish PH-ILD enrollment in 2028 and has set a 2029 target for an L606 new drug application submission, outlining two development milestones across consecutive years.
The 2029 submission target falls in the calendar year after the enrollment milestone.
John Kim
John Kim reports on the digital-asset business for TokenPost. Send corrections or tips to info@tokenpost.com.